Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac hydroxyethylpyrrolidine is a salt of the non-steroidal anti-inflammatory drug (NSAID) diclofenac. It functions as a potent inhibitor of the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which are responsible for the production of prostaglandins that mediate pain, fever, and inflammation. In the clinical trial conducted by the Specialized Arab Hospital, this specific formulation was administered via intramuscular injection to evaluate its efficacy in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. By inhibiting the early inflammatory response triggered during the ERCP procedure, the drug aims to reduce the incidence and severity of acute pancreatitis in high-risk patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac hydroxyethylpyrrolidine.